Changing Lives Fundraiser

EVENT INFORMATION: Friday, February 15, 2019 — 6:00 – 10:00 PM The Salem Waterfront Hotel — 225 Derby Street Salem, MA 01970 Food Open Cash Bar Silent Auction Fun & Dancing with DJ Nick! Theme: Wear Green! Prize awarded for best dressed! To purchase tickets, please contact Caitlin Fortuna at: https://changinglivesfund.wixsite.com/fundraiser Adults: $23 Children: $20 (Under 3 yrs: Free) Event proceeds after expenses will go to the Cholangiocarcinoma...

Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Study Name Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy ClinicalTrials.gov Identifier (if applicable) NCT03639935 Clinical Trial Category (check all that apply) Beyond First Line Therapy Study Center Institution Name University of Michigan Institution Address 1500 E Medical Center Dr., Rogel Cancer Center City Ann Arbor State Michigan Zip Code 48109 Country United States Phone (734) 936-4991 List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute Vanderbilt University Medical Center Study Contacts Principal Investigator Vaibhav Sahai, MD P.I. Phone (734) 936-4991 P.I. Email CTSU-Oncology-Multisite@med.umich.edu Study Coordinator Dominique Dippman, RN Study Coordinator Phone (734) 647-8902 Study Coordinator Email CTSU-Oncology-Multisite@med.umich.edu OVERVIEW – in layman’s terms (150 words max) The investigators are studying the benefit of daily oral targeted therapy (rucaparib) in conjunction with every 2 week infusional immunotherapy (nivolumab) in...

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Study Name Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT03678883 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Targeted Therapy Other Novel Therapy Study Center Institution Name Rhode Island Hospital Institution Address rovidence, Rhode Island, United States, 02903 City Providence State Rhode Island Zip Code 02903 Country United States Phone (401) 444-3234 Website https://www.lifespan.org/centers-services/cancer-research-and-clinical-trials Study Contacts Principal Investigator Benedito Carneiro, MD P.I. Phone (401) 444-3234 P.I. Email Benedito.Carneiro@Lifespan.org Study Coordinator Jennifer Renaud Study Coordinator Phone (401) 444-3234 Study Coordinator Email JRenaud@Lifespan.org OVERVIEW – in layman’s terms (150 words max) A clinical trial of a new drug known as 9-ING-41, that will take place in patients with tumors or cancers that affect the blood and lymph system. 9-ING-41...

Tree Topp

Study Name Tree Topp ClinicalTrials.gov Identifier (if applicable) NCT03093870 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Study Center Institution Name UT MD Anderson Cancer Center Institution Address University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 426, FC10.2051 City Houston State TX Zip Code 77030 Phone 1-877-250-3770 Website mdanderson.org Study Contacts Principal Investigator Dr. Milind Javle P.I. Phone (713) 794-1623 P.I. Email mjavle@mdanderson.org Study Coordinator Kimberly Ross Study Coordinator Phone 713-794-1623 Study Coordinator Email kdross@mdanderson.org List additional Study Coordinators (include phone number and email) Charlotte, North Carolina – Levine Cancer Institute, Carolinas Healthcare System 1021 Morehead Medical Dr.  Charlotte, NC  28204; (980) 442-2000 Contact: Study Coordinator – Melani Terry, (980)-442-2157, Melani.Terry@atriumhealth.org Dallas, Texas – Texas Oncology, P.A., Texas Oncology Sammons Cancer Center 3410 Worth Street, Suite 730 , Dallas, TX 75246; www.texasoncology.com Contact: Study Coordinator -Catinna Mallett, (214)-370-1949 Detroit, Michigan – Karmanos Cancer...

GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients

Study Name GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients ClinicalTrials.gov Identifier (if applicable) NCT03316222 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Other Novel Therapy Study Center Institution Name Memorial Sloan Kettering Institution Address 300 E 53rd St City New York State New York Zip Code 10065 Study Contacts Principal Investigator Pr James Harding P.I. Phone (646) 888-4314 P.I. Email hardinj1@mskcc.org List additional Principal Investigators (include phone number and email) Pr Ghassan Abou-Alfa, (646) 888-4184, abou-alg@mskcc.org Study Coordinator Amanda Simms Study Coordinator Phone (646) 888-4314 Study Coordinator Email simmsa@mskcc.org List additional Study Coordinators (include phone number and email) Brittanie Millans, millangb@mskcc.org OVERVIEW – in layman’s terms (150 words max) This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine...

The 2019 Annual Conference T-Shirt Design Contest

CCF is excited to announce our Annual Conference t-shirt logo contest. The logos will be printed on a white sport t-shirt with green 3/4 sleeves. Contest Rules Use this entry form to submit your logo design Limit design to a maximum of 2 colors Limit design to no larger than 10 inches square 5 designs will be posted on our Facebook page for voting. The winning design will be the logo with the most “likes” Submission deadline is Sunday, September 30th Questions? Email jordan.giles@cholangiocarcinoma.org   Name* First Last What is your relationship with cholangiocarcinoma?Patient (personally diagnosed)CaregiverFriend or Relative of PatientOtherAddress Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarrussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland...

Thoughts and Memories of Marion Schwartz

Marion and I worked together daily for over 10 years building the foundation and we’ve talked often since her retirement. She worked with many of you over the years to make sure the patient voice was considered in all endeavors and she admired the way you treated “her” patients. She took great pride in her work and considered you friends and colleagues. Today, at CCF we will be thinking of Marion, all she accomplished and all those she personally shepherded through life with compassion and great tenderness. She had a wonderful gift that she shared with all of us. She was and will continue to be an enormous blessing to our community. Love to all, Stacie C. Lindsey President & Founder Cholangiocarcinoma Foundation We will all treasure great memories of Marion and her passion for improving care for patients with cholangiocarcinoma. Deepest condolences to her family. Dr. Lewis Roberts...

A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma

Study Name A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) NCT03086993 Clinical Trial Category (check all that apply) Chemotherapy First Line Therapy Targeted Therapy Study Center Institution Name Duke University Medical Center Institution Address 30 Duke Medicine Circle City Durham State North Carolina Zip Code 27710 Study Contacts Principal Investigator Sabino Zani P.I. Phone (919) 684-6553 P.I. Email sabino.zani@duke.edu Study Coordinator Kimberly Turnage Study Coordinator Phone (919) 681-5559 Study Coordinator Email kimberly.turnage@duke.edu OVERVIEW – in layman’s terms (150 words max) Patients with intrahepatic cholangiocarcinoma who enroll in this study will receive either Melphalan with the investigational Hepatic Delivery System (called Melphalan/HDS) or Cisplatin and Gemcitabine alone, which is standard of care.  Patients who enroll will receive gem/cis followed by melphalan, compared to gem/cis. Enrollment 5...

A Study of TAS-120 in Patients With Advanced Solid Tumors

Study Name A Study of TAS-120 in Patients With Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT02052778 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 55 Fruit Street City Boston State Massachusetts Zip Code 02114 List additional Institutions (include address, phone number, and website) 1. Sarah Cannon Research Institute – 93 Harley Street, London, W1G 6AD, UK 2. Institute Goustave-Roussy – 39 Rue Camille Desmoulins, Villejuif Cedex, Paris, 94805, France 3. Royal Melbourne Hospital – 305 Grattan Street, Melbourne, Victoria, 3000 Australia 4. Greenville Health System ITOR – 900 W. Faris Rd., CTC 3rd floor, Greenville, SC 29605, USA 5. Centre Léon Bérard Bât – 28 rue Laennec, Lyon 69008, France 6. INSTITUT BERGONIE – 229 COURS DE L‘ARGONNE, BORDEAUX 33076 France 7. Pitié-Salpêtrière Hospital – 47-83 Bd de l’Hopital, Paris 75013, France 8. University Hospital Ramón y Cajal – Oficina de Ensayos Clínicos...

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Study Name A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer ClinicalTrials.gov Identifier (if applicable) NCT03482102 Clinical Trial Category (check all that apply) Beyond First Line Therapy Immunotherapy Radiation Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 55 Fruit Street City Boston State Massachusetts Zip Code 02114 List additional Institutions (include address, phone number, and website) This study is also being conducted at Dana Farber Cancer Institute (DFCI)/Brigham & Women’s Hospital (BWH). Study Contacts Principal Investigator Theodore S. Hong, MD P.I. Phone (617) 726-6050 P.I. Email TSHONG1@mgh.harvard.edu List additional Principal Investigators (include phone number and email) This study is also being conducted at Dana Farber Cancer Institute/Brigham & Women’s Hospital. Site Principal Investigator: Jeffrey A. Meyerhardt, MD, MPH Phone: 617-632-6855 Email: Jeffrey_Meyerhardt@dfci.harvard.edu Study Coordinator Leilana Ly Study Coordinator Phone (617) 726-8114 Study Coordinator Email LLY2@mgh.harvard.edu List additional Study...

A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Study Name A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT03329950 Clinical Trial Category (check all that apply) Beyond First Line Therapy Immunotherapy Study Center Institution Name HonorHealth Research Insititute Institution Address 10510 N. 92nd Street City Scottsdale State Arizona Zip Code 85258 Phone (480) 323-1350 List additional Institutions (include address, phone number, and website) Icahn School of Medicine at Mount Sinai (New York, NY 10029. 212-824-8449). Memorial Sloan Kettering Cancer Center (New York, NY 10065. 646-888-4384) Providence Portland Medical Center (Portland, OR 97213. 503-215-7192) Abramson Cancer Center at the University of Pennsylvania (Philadelphia, PA 19104. 215-614-7677) Study Contacts Principal Investigator Michael Gordon, MD P.I. Phone (480) 323-1350 P.I. Email michael.gordon@honorhealth.com List additional Principal Investigators (include phone number and email) Nina Bhardwaj, MD at Mount Sinai (contact Melissa Diamond at 212-824-8449 or melissa.diamond@mssm.edu) Danny Khalil,...

Avery’s Ice Cream for a Cure

Avery has a huge love for ice cream and all things chocolate. She also wants to help find a cure for cancer, specifically cholangiocarcinoma, in memory of her grandmother. So this sweet 9 year old decided to use her love of ice cream to raise money and awareness for the The Cholangiocarcinoma Foundation. Avery‘s Ice Cream for a Cure fundraiser in February generated over...
Translate »

Pin It on Pinterest